Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB DEX versus EPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB DEX versus EPICORT.
AEROSEB-DEX vs EPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
2 puffs (100 mcg each) intranasally twice daily
IV: 50 mg every 8 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid